Answers are grounded in this paper and cite their sources.
Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA. Matrilin-2 protein expression was similarly elevated in the majority of sporadic PA, but in only one neurofibromatosis 1-associated PA with an unusually aggressive clinical phenotype. These results suggest that matrilin-2 may be a specific and clinically useful biomarker for discriminating between indolent and clinically aggressive PA.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: